WO2007052067A3 - Von willebrand factor (vwf) binding peptides - Google Patents

Von willebrand factor (vwf) binding peptides Download PDF

Info

Publication number
WO2007052067A3
WO2007052067A3 PCT/GB2006/004160 GB2006004160W WO2007052067A3 WO 2007052067 A3 WO2007052067 A3 WO 2007052067A3 GB 2006004160 W GB2006004160 W GB 2006004160W WO 2007052067 A3 WO2007052067 A3 WO 2007052067A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
vwf
binding peptides
von willebrand
willebrand factor
Prior art date
Application number
PCT/GB2006/004160
Other languages
French (fr)
Other versions
WO2007052067A2 (en
Inventor
Richard Farndale
Nicolas Raynal
Johannes Lisman
Groot Philip De
Original Assignee
Cambridge Entpr Ltd
Umc Utrecht Holding Bv
Richard Farndale
Nicolas Raynal
Johannes Lisman
Groot Philip De
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Entpr Ltd, Umc Utrecht Holding Bv, Richard Farndale, Nicolas Raynal, Johannes Lisman, Groot Philip De filed Critical Cambridge Entpr Ltd
Publication of WO2007052067A2 publication Critical patent/WO2007052067A2/en
Publication of WO2007052067A3 publication Critical patent/WO2007052067A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/222—Platelet disorders

Abstract

This invention relates to short triple-helical collagen peptides that are recognised by VWF A3 domain and which consist of the sequence N1RGX3X4GX5X6GX7N2, wherein; X3 is any amino acid except G, X4 is O or P, X5 is any amino acid except G or A, X6 is any amino acid except G, X7 is any amino acid except G or A, and; N1 and N2 are amino acid sequences consisting, independently, of 0 to 10 amino acid residues. Peptides described herein may be useful in the treatment of thrombosis and the diagnosis of bleeding disorders, as well as in the construction of synthetic collagens.
PCT/GB2006/004160 2005-11-07 2006-11-07 Von willebrand factor (vwf) binding peptides WO2007052067A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0522748.3 2005-11-07
GBGB0522748.3A GB0522748D0 (en) 2005-11-07 2005-11-07 Collagen peptides, methods and uses

Publications (2)

Publication Number Publication Date
WO2007052067A2 WO2007052067A2 (en) 2007-05-10
WO2007052067A3 true WO2007052067A3 (en) 2007-08-02

Family

ID=35516535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/004160 WO2007052067A2 (en) 2005-11-07 2006-11-07 Von willebrand factor (vwf) binding peptides

Country Status (2)

Country Link
GB (1) GB0522748D0 (en)
WO (1) WO2007052067A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2695288A1 (en) 2007-08-01 2009-02-05 Ethicon, Inc. Collagen-related peptides and uses thereof
US20100021527A1 (en) 2008-07-25 2010-01-28 Chunlin Yang Collagen-related peptides and uses thereof and hemostatic foam substrates
EP2543677A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
FR2997083B1 (en) 2012-10-19 2014-12-12 Nvh Medicinal RECOMBINANT PROTEINS DERIVED FROM COLLAGEN WITH WILLEBRAND FACTOR BINDING ACTIVITY
CN106066401B (en) * 2014-03-07 2018-11-23 重庆早柒天生物科技股份有限公司 Biomarker VWF and ADAMTS13 and its purposes in liver cirrhosis diagnosis reagent
WO2018022553A1 (en) 2016-07-25 2018-02-01 Cerapedics, Inc. Peptide-coated calcium phosphate particles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050281A2 (en) * 1998-03-30 1999-10-07 Cambridge University Technical Services Limited Collagen peptides and uses thereof
WO2001070772A2 (en) * 2000-03-23 2001-09-27 Pierre Fabre Medicament Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid
WO2004031206A2 (en) * 2002-09-30 2004-04-15 Shriners Hospitals For Children Products for regulating the degradation of collagen and methods for indentifying same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999050281A2 (en) * 1998-03-30 1999-10-07 Cambridge University Technical Services Limited Collagen peptides and uses thereof
WO2001070772A2 (en) * 2000-03-23 2001-09-27 Pierre Fabre Medicament Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of an addition salt to an acid
WO2004031206A2 (en) * 2002-09-30 2004-04-15 Shriners Hospitals For Children Products for regulating the degradation of collagen and methods for indentifying same

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 124A, ISSN: 0006-4971 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2005 (2005-11-01), LISMAN TON ET AL: "Identification of the von Willebrand factor binding site in collagen using triple helical peptides", XP002425785, Database accession no. PREV200600182783 *
FARNDALE ET AL: "Collagen-induced platelet activation", BLOOD CELLS, MOLECULES AND DISEASES, LAJOLLA, US, vol. 36, no. 2, March 2006 (2006-03-01), pages 162 - 165, XP005345972, ISSN: 1079-9796 *
KNIGHT C GRAHAM ET AL: "Collagen-platelet interaction: Gly-Pro-Hyp is uniquely specific for platelet Gp VI and mediates platelet activation by collagen", CARDIOVASCULAR RESEARCH, vol. 41, no. 2, February 1999 (1999-02-01), pages 450 - 457, XP002425787, ISSN: 0008-6363 *
KRCO C J ET AL: "Identification of T cell determinants on human type II collagen recognized by HLA-DQ8 and HLA-DQ6 transgenic mice.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 AUG 1999, vol. 163, no. 3, 1 August 1999 (1999-08-01), pages 1661 - 1665, XP002425783, ISSN: 0022-1767 *
KRCO CHRISTOPHER J ET AL: "Characterization of the antigenic structure of human type II collagen", JOURNAL OF IMMUNOLOGY, vol. 156, no. 8, 1996, pages 2761 - 2768, XP002425781, ISSN: 0022-1767 *
LISMAN TON ET AL: "A single high-affinity binding site for von Willebrand factor in collagen III, identified using synthetic triple-helical peptides", BLOOD, vol. 108, no. 12, December 2006 (2006-12-01), pages 3753 - 3756, XP002425786, ISSN: 0006-4971 *
LITJENS P E M H ET AL: "A tripeptide mimetic of von Willebrand factor residues 981-983 enhances platelet adhesion to fibrinogen by signaling through integrin alpha(IIb)beta3.", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH JUN 2005, vol. 3, no. 6, June 2005 (2005-06-01), pages 1274 - 1283, XP002425784, ISSN: 1538-7933 *
LUNG F -D T ET AL: "Surface plasmon resonance detection of interactions between peptide fragments of N-telopeptide and its monoclonal antibodies", JOURNAL OF PEPTIDE RESEARCH, vol. 63, no. 4, April 2004 (2004-04-01), pages 365 - 370, XP002425782, ISSN: 1397-002X *

Also Published As

Publication number Publication date
WO2007052067A2 (en) 2007-05-10
GB0522748D0 (en) 2005-12-14

Similar Documents

Publication Publication Date Title
WO2007052067A3 (en) Von willebrand factor (vwf) binding peptides
WO2009067639A3 (en) Variants of c-type natriuretic peptide
ATE525082T1 (en) COMPSTATIN ANALOGUES WITH IMPROVED EFFECTS
EP1764370A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
DE60325770D1 (en) USE OF RIMEXOLONE FOR THE TREATMENT OF EYE DRYNESS
ME00185B (en) Specific binding agents of human angiopoietin-2
DE602005013788D1 (en) ckrox peptides and their analogs for the treatment of skin aging
EP2993187A3 (en) Antibodies directed to her-3 and uses thereof
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
DE60319325D1 (en) Process for the preparation of low molecular weight hydrogenated nitrile rubber
ATE417058T1 (en) DERIVATIVES OF THE Z-DOMAIN OF PROTEIN A OF STAPHYLOCOCCUS (SPA), WHICH INTERACT WITH AT LEAST ONE DOMAIN OF HUMAN FACTOR VIII
DE60330923D1 (en) Human coagulation factor VII polypeptides
WO2003037932A3 (en) Human coagulation factor vii polypeptides
DK1890559T3 (en) Citrus fruit fibers in processed meat
WO2006056987A3 (en) Leptin antagonists
CY1112875T1 (en) SFRP AND SUBSTITUTE PATTERNS INTERFERENCE WITH SFRP AND METHODS OF USE
ATE543833T1 (en) BMP-7 VARIANT COMPOSITIONS, METHODS AND USES
EP1860118A3 (en) Glycoprotein vi - fc fusion protein for treating vascular disorders
ATE401309T1 (en) USE OF 2-FUORO-3-KETO ESTERS TO PRODUCE 3-FUORO-6,7,8,9-TETRAHYDRO-4H-PYRIMIDOÄ1,2-AUPYRIMIDINE-4-ONENES
ATE547519T1 (en) CLOTTING FACTOR VII POLYPEPTIDES
DE60141588D1 (en) NUCLEIC ACID SEQUENCE AND PROTEIN THAT PLAYS A ROLE IN CELLULAR AGING
WO2006046073A3 (en) C1q related protein
ATE506370T1 (en) REAGENTS AND METHODS FOR FORMING DISULFIDE BONDS AND GLYCOSYLATION OF PROTEINS
WO2004039834A3 (en) Recombinant protein variants
DE50306876D1 (en) PROCESS FOR THE PREPARATION OF ALKYLARYLSULFONATE BY MODIFIED, DIMERIZED OLEFINE

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06808455

Country of ref document: EP

Kind code of ref document: A2